Articular cartilage extracellular matrix components (Articular cartilage ECM)

Articular cartilage extracellular matrix (ECM) components form the complex, non-cellular structural framework of hyaline cartilage, primarily consisting of a dense network of type II collagen fibers and large aggregating proteoglycans like aggrecan (NIH, 2022). This specialized matrix is essential for the mechanical properties of joints, providing high tensile strength and compressive resilience while facilitating low-friction movement through hydration and lubrication (Assay Genie, 2024). In degenerative conditions such as osteoarthritis, the homeostatic balance between ECM synthesis and degradation is disrupted, leading to the progressive loss of these structural components and subsequent joint failure (Physiology.org, 2020). Therapeutic interventions target the ECM by either replacing lost components through viscosupplementation or by stimulating chondrocytes to increase matrix production via anabolic signaling (NIH, 2024). Additionally, drugs are being developed to inhibit the proteolytic enzymes, such as MMP-13 and ADAMTS-5, that drive the catabolic breakdown of the matrix (MDPI, 2021). Monitoring the turnover of these components using biomarkers like CTX-II and COMP is critical for assessing disease severity and the efficacy of potential disease-modifying therapies (Nordic Bioscience, 2024). Overall, the integrity of the articular cartilage ECM is the primary determinant of joint health and a central focus for regenerative medicine.

Other names

Cartilage matrixChondrocyte extracellular matrixHyaline cartilage ECMCartilage matrisome

Viscosupplementation to restore joint lubrication, stimulation of chondrocyte anabolic pathways to increase matrix synthesis, and inhibition of catabolic proteases to prevent the enzymatic degradation of structural proteins.